OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders
The FDA approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]
Concerto HealthAI, offers a clinical insight generation platform that employs real-world data in its analyses
Published January 3, 2016 in Managed Healthcare Executive Is an HIV Vaccine on the horizon? There’s good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). These viral diseases are now more vulnerable because of improved gene-based targeting and communications around exposure from surveillance programs. Some feel, however, that policymakers could do […]